Structural Analysis of NAT Acetylation, Substrate Specificity and Polymorphisms
NAT 乙酰化、底物特异性和多态性的结构分析
基本信息
- 批准号:7652388
- 负责人:
- 金额:$ 22.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-01 至 2011-07-31
- 项目状态:已结题
- 来源:
- 关键词:Acetyl Coenzyme AAcetylationAffectAmino Acid SubstitutionAreaAromatic AminesArylamine N-AcetyltransferaseBindingBiological ModelsBladderCancer PatientCarcinogensCatalysisCaucasiansCaucasoid RaceCellsCellular biologyChemicalsComplementComplexControl GroupsCrystallizationDataDiseaseDrug Metabolic DetoxicationDyesEndoplasmic ReticulumEngineeringExhibitsGenetic PolymorphismGoalsHamstersHumanIn VitroKineticsKnowledgeLaboratoriesLeadLinkMalignant NeoplasmsMalignant neoplasm of urinary bladderModelingNAT2 geneNMR SpectroscopyNeurodegenerative DisordersNitrogenOutcomes ResearchPathway interactionsPesticidesPharmacologic SubstancePlayPopulationPredispositionPrincipal InvestigatorProcessPropertyProteinsPublishingQuality ControlRecruitment ActivityRefractoryResearchResearch MethodologyRoleSite-Directed MutagenesisSourceSpecificityStructureSubstrate SpecificitySurfaceSurface PropertiesSystemTestingTimeTobaccoToluidinesTrainingUbiquitinVariantWorkadductbasebladder cancer preventioncarcinogenesiscookinghuman NAT2 proteinin vivoinnovationmulticatalytic endopeptidase complexmutantpopulation basedpost-doctoral trainingpreventprogramsprotein aggregateprotein functionprotein misfoldingpublic health researchresearch studysuccessthree dimensional structure
项目摘要
DESCRIPTION (provided by applicant): Arylamine N-acetyltransferases (NATs) detoxify arylamine bladder carcinogens that are ingested as cooking, pesticide, tobacco, or dye byproducts. They perform this function by transferring to the arylamine an acetyl group from acetyl-CoA. Bladder cancer patients exhibit elevated levels of arylamine-adducts compared to control groups, some of which have been demonstrated to be poor substrates for NATs. As part of this proposal, we define the determinants of NAT substrate specificity to reveal why certain arylamine carcinogens are unable to be detoxified. NATs are highly polymorphic proteins and a large percentage of the population harbor NAT variants with reduced catalytic activity in vivo. We, and others, have recently demonstrated such variants to be rapidly degraded through the ubiquitin-proteasome pathway. One of our long-term goals is to use NATs as a model system to determine how ubiquitylation targets are identified in cells and to elucidate the mechanism(s) that lead to their delivery to the proteasome. This research will provide fundamental information on quality control pathways that exist to recognize and eliminate aberrant proteins. The following three general areas are pursued. 1) Develop a general model for NAT substrate specificity. NMR and steady state kinetics experiments are used to define the determinants of NAT substrate specificity and this knowledge used to generate variants that can acetylate additional arylamine carcinogens. 2) Determine the mechanisms that lead to NAT constitutive ubiquitylation. In previous work, we demonstrated NAT constitutive ubiquitylation to be linked to its aggregation state and our preliminary data indicate such ubiquitylation to occur at the endoplasmic reticulum. In the proposed research, we determine how NATs are recognized as aberrant, the determinants of their ubiquitylation, and whether they are processed through a common pathway that applies to other aggregated or mis-folded proteins. 3) Define how acetylation affects NAT structure and surface properties. The successful outcome of this research could aid in the prevention of bladder cancer and lead to new therapeutical strategies for diseases associated with mis-folded or aggregated proteins, including neurodegenerative diseases and cancer. Relevance of this research to public health This research has therapeutical implications for NAT-associated carcinogenesis, especially bladder cancer, as well as diseases associated misfolded or aggregated proteins, including neurodegenerative diseases. NATs detoxify chemicals known as arylamines and population-based studies have connected reduced NAT activity and arylamines that evade NAT detoxification to bladder cancer. We determine how certain arylamines evade NAT detoxification and why the NAT proteins of some people are destroyed before they can perform their protein function.
描述(由申请人提供):芳基胺N-乙酰转移酶(NAT)可使作为烹饪、农药、烟草或染料副产品摄入的芳基胺膀胱致癌物解毒。它们通过将乙酰辅酶A的乙酰基转移到芳胺上来实现这一功能。与对照组相比,膀胱癌患者表现出芳胺加合物水平升高,其中一些已被证明是NAT的不良底物。作为这项建议的一部分,我们定义的NAT底物特异性的决定因素,揭示为什么某些芳胺致癌物是无法解毒。NAT是高度多态性的蛋白质,并且很大比例的群体具有体内催化活性降低的NAT变体。我们和其他人最近已经证明了这些变体通过泛素-蛋白酶体途径快速降解。我们的长期目标之一是使用NAT作为模型系统,以确定如何在细胞中识别泛素化靶点,并阐明导致其传递到蛋白酶体的机制。这项研究将为识别和消除异常蛋白质的质量控制途径提供基本信息。在以下三个一般领域开展工作。1)开发NAT底物特异性的通用模型。NMR和稳态动力学实验用于定义NAT底物特异性的决定因素,并且该知识用于产生可以乙酰化另外的芳胺致癌物的变体。2)确定导致NAT组成性泛素化的机制。在以前的工作中,我们证明了NAT组成性泛素化与其聚集状态有关,我们的初步数据表明这种泛素化发生在内质网。在拟议的研究中,我们确定NAT如何被识别为异常,其泛素化的决定因素,以及它们是否通过适用于其他聚集或错误折叠蛋白质的共同途径进行处理。3)定义乙酰化如何影响NAT结构和表面性质。这项研究的成功结果可以帮助预防膀胱癌,并为与错误折叠或聚集蛋白质相关的疾病(包括神经退行性疾病和癌症)带来新的治疗策略。这项研究与公共卫生的相关性这项研究对NAT相关的致癌作用具有治疗意义,特别是膀胱癌,以及与错误折叠或聚集蛋白相关的疾病,包括神经退行性疾病。NAT可以解毒被称为芳基胺的化学物质,基于人群的研究将NAT活性降低和逃避NAT解毒的芳基胺与膀胱癌联系起来。我们确定了某些芳胺如何逃避NAT解毒,以及为什么有些人的NAT蛋白在它们能够发挥蛋白质功能之前就被破坏了。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kylie J. Walters其他文献
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export
RAS•GTP:RanGAP1 复合物的致癌非经典活性促进核蛋白输出
- DOI:
10.1038/s43018-024-00847-5 - 发表时间:
2024-11-11 - 期刊:
- 影响因子:28.500
- 作者:
Brajendra K. Tripathi;Nicole H. Hirsh;Xiaolan Qian;Marian E. Durkin;Dunrui Wang;Alex G. Papageorge;Ross Lake;Yvonne A. Evrard;Adam I. Marcus;Suresh S. Ramalingam;Mary Dasso;Karen H. Vousden;James H. Doroshow;Kylie J. Walters;Douglas R. Lowy - 通讯作者:
Douglas R. Lowy
hRpn13 shapes the proteome and transcriptome through epigenetic factors HDAC8, PADI4, and transcription factor NF-κB p50
HRPN13通过表观遗传因子HDAC8,PADI4和转录因子NF-κBP50塑造蛋白质组和转录组
- DOI:
10.1016/j.molcel.2023.11.035 - 发表时间:
2024-02-01 - 期刊:
- 影响因子:16.600
- 作者:
Vasty Osei-Amponsa;Monika Chandravanshi;Xiuxiu Lu;Valentin Magidson;Sudipto Das;Thorkell Andresson;Marzena Dyba;Venkata R. Sabbasani;Rolf E. Swenson;Caroline Fromont;Biraj Shrestha;Yongmei Zhao;Michelle E. Clapp;Raj Chari;Kylie J. Walters - 通讯作者:
Kylie J. Walters
Characterizing protein-protein complexes and oligomers by nuclear magnetic resonance spectroscopy.
通过核磁共振波谱表征蛋白质-蛋白质复合物和寡聚物。
- DOI:
- 发表时间:
2001 - 期刊:
- 影响因子:0
- 作者:
Kylie J. Walters;A. E. Ferentz;Brian J. Hare;Patricia Hidalgo;Alan Jasanoff;Hiroshi Matsuo;Gerhard Wagner - 通讯作者:
Gerhard Wagner
An adaptive peptide-binding site in ubiquitin receptor hRpn13 revealed by structural studies
通过结构研究揭示了泛素受体 hRpn13 中的一个适应性肽结合位点
- DOI:
10.1038/s41467-025-60843-w - 发表时间:
2025-07-01 - 期刊:
- 影响因子:15.700
- 作者:
Bakar Hassan;Monika Chandravanshi;Martin Y. Ng;Hitendra Negi;Brice A. P. Wilson;Kylie J. Walters - 通讯作者:
Kylie J. Walters
HIV-1 vif mediates ubiquitination of the proximal protomer in the APOBEC3H dimer to induce degradation
HIV-1 vif 介导 APOBEC3H 二聚体中近侧原体的泛素化以诱导降解
- DOI:
10.1038/s41467-025-60984-y - 发表时间:
2025-07-01 - 期刊:
- 影响因子:15.700
- 作者:
Katarzyna A. Skorupka;Kazuhiro Matsuoka;Bakar Hassan;Rodolfo Ghirlando;Vanivilasini Balachandran;Ting-Hua Chen;Kylie J. Walters;Celia A. Schiffer;Matthias Wolf;Yasumasa Iwatani;Hiroshi Matsuo - 通讯作者:
Hiroshi Matsuo
Kylie J. Walters的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kylie J. Walters', 18)}}的其他基金
NMR Structural Studies of Ubiquitin Receptor Protein Complexes
泛素受体蛋白复合物的 NMR 结构研究
- 批准号:
7990131 - 财政年份:2010
- 资助金额:
$ 22.02万 - 项目类别:
NMR Structural Studies of Ubiquitin Receptor Protein Complexes
泛素受体蛋白复合物的 NMR 结构研究
- 批准号:
8104087 - 财政年份:2010
- 资助金额:
$ 22.02万 - 项目类别:
FUNCTION PROFILE OF UBIQUITIN RECEPTOR RPN13
泛素受体 RPN13 的功能概况
- 批准号:
8168967 - 财政年份:2010
- 资助金额:
$ 22.02万 - 项目类别:
NMR Structural Studies of Ubiquitin Receptor Protein Complexes
泛素受体蛋白复合物的 NMR 结构研究
- 批准号:
8403784 - 财政年份:2010
- 资助金额:
$ 22.02万 - 项目类别:
NMR Structural Studies of Ubiquitin Receptor Protein Complexes
泛素受体蛋白复合物的 NMR 结构研究
- 批准号:
8207198 - 财政年份:2010
- 资助金额:
$ 22.02万 - 项目类别:
Defining how the Proteasome Recognizes its Ubiquitylated Substrates
定义蛋白酶体如何识别其泛素化底物
- 批准号:
7847348 - 财政年份:2009
- 资助金额:
$ 22.02万 - 项目类别:
FUNCTION PROFILE OF UBIQUITIN RECEPTOR RPN13
泛素受体 RPN13 的功能概况
- 批准号:
7954676 - 财政年份:2009
- 资助金额:
$ 22.02万 - 项目类别:
相似海外基金
Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
- 批准号:
EP/Y000331/1 - 财政年份:2023
- 资助金额:
$ 22.02万 - 项目类别:
Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
- 批准号:
10677295 - 财政年份:2023
- 资助金额:
$ 22.02万 - 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
- 批准号:
10635599 - 财政年份:2023
- 资助金额:
$ 22.02万 - 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
- 批准号:
10752320 - 财政年份:2023
- 资助金额:
$ 22.02万 - 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
- 批准号:
478927 - 财政年份:2023
- 资助金额:
$ 22.02万 - 项目类别:
Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
- 批准号:
10855703 - 财政年份:2023
- 资助金额:
$ 22.02万 - 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
- 批准号:
10654210 - 财政年份:2023
- 资助金额:
$ 22.02万 - 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
- 批准号:
10733915 - 财政年份:2023
- 资助金额:
$ 22.02万 - 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
- 批准号:
10667952 - 财政年份:2023
- 资助金额:
$ 22.02万 - 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
- 批准号:
10726986 - 财政年份:2023
- 资助金额:
$ 22.02万 - 项目类别: